Heightened awareness and surge in prevalence of colorectal cancer (CRC), government screening programs, and investment strategies are expected to fuel the Europe fecal immunochemical test (FIT) market size. Growth in number of CRC cases driven by the aging population and lifestyle-related risk factors further contributes to market progress.
FIT is the preferred screening method due to its noninvasive nature and high accuracy in detecting occult blood, especially among older people. Kits/reagents are dominant in the market, as they help in hassle-free testing, minimizing testing error.
Hospitals & diagnostics centers play a major role due to their infrastructure and trained personnel. The homecare segment is positioned for massive growth in the market, largely because of convenience for patients who are unable to move around comfortably.
The early diagnosis of colorectal cancer (CRC) with efficient screening technologies such as FIT, which helps detect blood even in minor quantity in stool with high sensitivity and specificity, is important to improve patient health outcomes. Unlike traditional guaiac fecal occult blood tests (gFOBT), change in diet does not affect the sensitivity of FIT tests.
European guidelines recommend FIT over gFOBT for CRC screening. This helps reduction of unnecessary colonoscopies and associated costs. National Institute for Health and Care Excellence (NICE) guidelines advocate FIT screening for primary care referrals, particularly for symptomatic patients, optimizing colonoscopy use and enhancing overall patient care.
Europe contributed 34.3% of the global FIT market in 2023 and is projected to grow at a CAGR of 7.5% from 2024 to 2034. Major diagnostics firms are entering the FIT market through capital fund deals, enhancing market competitiveness and speeding up the adoption of new diagnostic technologies.
| Attribute | Detail |
|---|---|
| Driver | Increase in Awareness of Early Cancer Detection |
Colorectal cancer (CRC) is a major concern in Europe, especially in Ireland, where the incidence and fatality rates are higher than the EU average. In 2011, Ireland reported 2,270 new CRC cases and 910 deaths, accounting for 12.9% of all invasive cancers and 11.1% of all cancer fatalities.
The high incidence and mortality rates from colorectal cancer (CRC) emphasizes the importance of early detection and treatment of CRC. Nearly 75% of people desire to be diagnosed for CRC, but 33% of them would decline a colonoscopy due to fear of pain.
Inadequate knowledge about fecal occult blood tests (FOBT) results in an opportunity for education and outreach. Screening methods that encourage non-invasive diagnosis procedures, such as FIT, drive industry growth by aligning patient preferences with healthcare standards.
The use of FIT as a primary screening approach saves human lives and helps in lowering healthcare costs, eventually improving public health outcomes throughout Europe and enhancing the Europe fecal immunochemical test (FIT) market value.
The Europe fecal immunochemical test (FIT) market segmentation based on product type includes kits & reagents, analyzers, and others. The kits & reagents segment dominated the market as they are critical for the accuracy and reliability of fecal immunochemical test (FIT) findings, since they comprise necessary ingredients such as buffer solutions, reagents, and test strips.
According to the European Commission, persons aged 65 and older account for more than 60% of new cancer diagnoses, emphasizing the importance of efficient screening technologies such as FIT for senior patients.
FIT kits and reagents are critical for improving the accuracy and reliability of CRC screening, lowering errors, and instilling trust in healthcare practitioners and patients. As awareness of CRC and earlier detection grows, so will the need for FIT kits and reagents, offering lucrative Europe fecal immunochemical test (FIT) market opportunities to manufacturers and suppliers.
As per the Europe fecal immunochemical test (FIT) market report, based on end-user, hospitals & diagnostics centers are likely to dominate the industry, ascribed to existing infrastructure, sophisticated equipment, and skilled healthcare staff.
Their capacity to offer rapid compensation through health-care providers and insurance companies result in high preference for diagnosis in FIT screening.
However, the growing homecare settings sector provides more easy screening choices for elders and handicapped people, reducing healthcare inequities and improving the accessibility of FIT testing.
The combination of institutional leadership from hospitals & diagnostics centers, as well as the growing homecare settings segment, indicates a strong market development trajectory for FIT in Europe.
| Attribute | Detail |
|---|---|
| Leading Country | Germany |
According to the Europe fecal immunochemical test (FIT) market analysis, currently in Europe, Germany is leading the landscape. In Germany, CRC incidence is third in males following prostate and lung cancer, and second in females after breast cancer, making it the common cause of cancer-related mortality in 2019.
Clinical guidelines, volunteer audits, and national training programs are all examples of initiatives aimed at improving care in the country.
National screening systems in European countries, where FIT is an important step in healthcare is fueling market expansion.
Initiatives such as the European Commission's Beating Cancer Plan aims to screen a significant proportion of eligible populations by 2025, thus promoting standardized screening methodologies, improving public awareness, and enabling universal access to screening.
This step addresses current healthcare challenges while laying the framework for long-term market development.
Leading players in the Europe fecal immunochemical test (FIT) market are adopting strategies such as development of products and collaborative partnerships. The market is highly competitive and has a strong presence of key players.
Abbott Rapid Diagnostics, Una Health, Alpha Laboratories Ltd, BIOHIT HealthCare Ltd, Sysmex UK, MAST Group Ltd, Epigenomics AG, Alfresa Pharma Corporation, Aidian Oy, Minaris Medical, Immundiagnostik Ag, Sentinel Diagnostics, Eiken Chemical Co. Ltd, BTNX Inc., and R-Biopharm are the prominent fecal immunochemical test (FIT) market manufacturers profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Value in 2023 | US$ 1.4 Bn |
| Forecast (Value) in 2034 | US$ 2.9 Bn |
| Growth Rate (CAGR) | 7.1% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 1.4 Bn in 2023
It is projected to reach more than US$ 2.9 Bn by the end of 2034
The CAGR is anticipated to be 7.1% from 2024 to 2034
Increase in awareness about early cancer detection
By product type, the kits and reagents segment accounted for major share in 2023
Germany is expected to account for major share during the forecast period
Abbott Rapid Diagnostics, Una Health, Alpha Laboratories Ltd, BIOHIT HealthCare Ltd, Sysmex UK, MAST Group Ltd, Epigenomics AG, Alfresa Pharma Corporation, Aidian Oy, Minaris Medical, Immundiagnostik Ag, Sentinel Diagnostics, Eiken Chemical Co. Ltd, BTNX Inc., and R-Biopharm
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fecal Immunochemical Test (FIT) Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5. Key Insights
5.1. Key Product/Brand Analysis
5.2. Technology Outlook
5.3. Overview: National Screenings Program Scenario
5.4. Disease Prevalence & Incidence Rate in Europe
5.5. Regulatory Scenario
5.6. Pricing Analysis
6. Europe Fecal Immunochemical Test (FIT) Market Analysis and Forecast, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2020-2034
6.3.1. Kits & Reagents
6.3.2. Analyzers
6.3.3. Others (Collection Devices etc.)
6.4. Market Attractiveness By Product Type
7. Europe Fecal Immunochemical Test (FIT) Market Analysis and Forecasts, By End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By End-user, 2020-2034
7.3.1. Hospitals & Diagnostics Centers
7.3.2. Specialty Clinics
7.3.3. Homecare Settings
7.3.4. Research Institutes
7.4. Market Attractiveness By End-user
8. Europe Fecal Immunochemical Test (FIT) Market Analysis and Forecasts, By Country/Sub-region
8.1. Key Findings
8.2. Market Value Forecast By Country/Sub-region
8.2.1. Germany
8.2.2. UK
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Market Attractiveness By Country/Sub-region
9. Germany Fecal Immunochemical Test (FIT) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Product Type, 2020-2034
9.2.1. Kits & Reagents
9.2.2. Analyzers
9.2.3. Others (Collection Devices etc.)
9.3. Market Value Forecast By End-user, 2020-2034
9.3.1. Hospitals & Diagnostics Centers
9.3.2. Specialty Clinics
9.3.3. Homecare
9.3.4. Research Institutes
9.4. Market Value Forecast By Country, 2020-2034
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By End-user
10. UK Fecal Immunochemical Test (FIT) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product Type, 2020-2034
10.2.1. Kits & Reagents
10.2.2. Analyzers
10.2.3. Others (Collection Devices etc.)
10.3. Market Value Forecast By End-user, 2020-2034
10.3.1. Hospitals & Diagnostics Centers
10.3.2. Specialty Clinics
10.3.3. Homecare
10.3.4. Research Institutes
10.4. Market Value Forecast By Country, 2020-2034
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By End-user
11. France Fecal Immunochemical Test (FIT) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product Type, 2020-2034
11.2.1. Kits & Reagents
11.2.2. Analyzers
11.2.3. Others (Collection Devices etc.)
11.3. Market Value Forecast By End-user, 2020-2034
11.3.1. Hospitals & Diagnostics Centers
11.3.2. Specialty Clinics
11.3.3. Homecare
11.3.4. Research Institutes
11.4. Market Value Forecast By Country, 2020-2034
11.5. Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By End-user
12. Italy Fecal Immunochemical Test (FIT) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product Type, 2020-2034
12.2.1. Kits & Reagents
12.2.2. Analyzers
12.2.3. Others (Collection Devices etc.)
12.3. Market Value Forecast By End-user, 2020-2034
12.3.1. Hospitals & Diagnostics Centers
12.3.2. Specialty Clinics
12.3.3. Homecare
12.3.4. Research Institutes
12.4. Market Value Forecast By Country, 2020-2034
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By End-user
13. Spain Fecal Immunochemical Test (FIT) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product Type, 2020-2034
13.2.1. Kits & Reagents
13.2.2. Analyzers
13.2.3. Others (Collection Devices etc.)
13.3. Market Value Forecast By End-user, 2020-2034
13.3.1. Hospitals & Diagnostics Centers
13.3.2. Specialty Clinics
13.3.3. Homecare
13.3.4. Research Institutes
13.4. Market Value Forecast By Country, 2020-2034
13.5. Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By End-user
14. Rest of Europe Fecal Immunochemical Test (FIT) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product Type, 2020-2034
14.2.1. Kits & Reagents
14.2.2. Analyzers
14.2.3. Others (Collection Devices etc.)
14.3. Market Value Forecast By End-user, 2020-2034
14.3.1. Hospitals & Diagnostics Centers
14.3.2. Specialty Clinics
14.3.3. Homecare
14.3.4. Research Institutes
14.4. Market Attractiveness Analysis
14.4.1. By Product Type
14.4.2. By End-user
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2023)
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Una Health
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Alpha Laboratories Ltd
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. BIOHIT HealthCare Ltd
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Sysmex UK
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. MAST Group Ltd
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Epigenomics AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Alfresa Pharma Corporation
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Aidian Oy
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Minaris Medical
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Immundiagnostik Ag
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Sentinel s
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Eiken Chemical Co.ltd
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. BTNX Inc.
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Product Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. R-Biopharm
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Product Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview
List of Tables
Table 01: Global Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 02: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Type, 2020-2034
Table 03: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 04: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 05: Germany Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Product Type, 2020-2034
Table 06: Germany Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 07: UK Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Product Type, 2020-2034
Table 08: UK Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 09: France Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Product Type, 2020-2034
Table 10: France Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 11: Italy Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Product Type, 2020-2034
Table 12: Italy Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Spain Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Product Type, 2020-2034
Table 14: Spain Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 15: Rest of Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by Product Type, 2020-2034
Table 16: Rest of Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast, 2020-2034
Figure 02: Global Fecal Immunochemical Test (FIT) Market Value Share, by Product Type, 2023
Figure 03: Global Fecal Immunochemical Test (FIT) Market Value Share, by End-user, 2023
Figure 04: Global Fecal Immunochemical Test (FIT) Market Value Share, by Region, 2023
Figure 05: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by Product Type, 2023 and 2034
Figure 06: Europe Fecal Immunochemical Test (FIT) Market Share Analysis, by Product Type, 2023
Figure 07: Europe Fecal Immunochemical Test (FIT) Market Share Analysis, by Product Type, 2034
Figure 08: Europe Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 09: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn), by Kits & Reagents, 2020‒2034
Figure 10: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Kits & Reagents, 2023 and 2034
Figure 11: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn), by Analyzers, 2020‒2034
Figure 12: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Analyzers, 2023 and 2034
Figure 13: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn), by Others, 2020‒2034
Figure 14: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Analyzers, 2023 and 2034
Figure 15: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 16: Europe Fecal Immunochemical Test (FIT) Market Share Analysis, by End-user, 2023
Figure 17: Europe Fecal Immunochemical Test (FIT) Market Share Analysis, by End-user, 2034
Figure 18: Europe Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by End-user, 2024-2034
Figure 19: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn), by Hospitals & Diagnostics Centers 2020‒2034
Figure 20: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Hospitals & Diagnostics Centers, 2023 and 2034
Figure 21: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn), by Specialty Clinics, 2020‒2034
Figure 22: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Specialty Clinics, 2023 and 2034
Figure 23: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn), by Homecare, 2020‒2034
Figure 24: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Homecare, 2023 and 2034
Figure 25: Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn), by Research institutes, 2020‒2034
Figure 26: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Research institutes, 2023 and 2034
Figure 27: Europe Fecal Immunochemical Test (FIT) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 28: Europe Fecal Immunochemical Test (FIT) Market Share Analysis, by Region, 2023
Figure 29: Europe Fecal Immunochemical Test (FIT) Market Share Analysis, by Region, 2034
Figure 30: Europe Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Country/Sub-region, 2023-2034
Figure 31: Germany Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 32: Germany Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by Product Type, 2023 and 2034
Figure 33: Germany Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 34: Germany Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 35: Germany Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: UK Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 37: UK Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by Product Type, 2023 and 2034
Figure 38: UK Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 39: UK Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 40: UK Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by End-user, 2024-2034
Figure 41: France Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 42: France Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by Product Type, 2023 and 2034
Figure 43: France Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 44: France Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 45: France Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by End-user, 2024-2034
Figure 46: Italy Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 47: Italy Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by Product Type, 2023 and 2034
Figure 48: Italy Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 49: Italy Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 50: Italy Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by End-user, 2024-2034
Figure 51: Spain Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 52: Spain Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by Product Type, 2023 and 2034
Figure 53: Spain Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 54: Spain Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 55: Spain Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by End-user, 2024-2034
Figure 56: Rest of Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 57: Rest of Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by Product Type, 2023 and 2034
Figure 58: Rest of Europe Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 59: Rest of Europe Fecal Immunochemical Test (FIT) Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 60: Rest of Europe Fecal Immunochemical Test (FIT) Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Europe Fecal Immunochemical Test (FIT) Market
